Almotriptan: A review of its use in migraine

Drugs

Volumn 62, Issue 2, 2002, Pages 387-414

  Keam, Susan J ^a   Goa, Karen L ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Almotriptan; Migraine; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; ELETRIPTAN; FLUOXETINE; KETOCONAZOLE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PARACETAMOL; PROPRANOLOL; RIZATRIPTAN; SEROTONIN 1A RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 1F RECEPTOR; SUMATRIPTAN; VERAPAMIL; ZOLMITRIPTAN;

BONE PAIN; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG CONTAMINATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; MIGRAINE; NAUSEA; NONHUMAN; PARESTHESIA; REVIEW; SOMNOLENCE; VERTIGO; VOMITING;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0036178434     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262020-00010     Document Type: Review

References (102)

1. Prevalence of migraine headache in the United States: Relation to age, income, race and other sociodemographic factors
2. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy?
3. One-year prevalence of migraine in Sweden: A population-based study in adults
4. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
5. Overview of diagnosis and treatment of migraine
6. Migraine with aura and migraine without aura: An epidemiological study
7. A study of migraine and its effects in a working population
8. Work-related disability: Results from the American migraine study
9. Headache epidemiology: Emphasis on migraine
10. HIT6 scores discriminate among headache sufferers differing in headache-associated workplace productivity loss
11. Role of the workplace in migraine disease management
12. Pathophysiology of migraine: New insights
13. The effect of serotonin on cranial vessels and its significance in migraine
14. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects
15. Serotonin and migraine
16. Nuevas perspectivas en el tratamiento de la migrãna
17. Pharmacological characterization of almotriptan: An indolic 5-HT receptor agonist for the treatment of migraine
18. 1D receptors
19. Vascular effects of the new antimigraine agent almotriptan on human cranial and peripheral arteries
20. Functional profile of almotriptan in animal models predictive of antimigraine activity
21. Cardiovascular safety profile of almotriptan, a new indolic derivative for the treatment of migraine
22. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers
23. Oral pharmacokinetics of the new antimigraine agent almotriptan in young and elderly healthy volunteers
24. 1B/D agonist in migraine
25. 1B/1D agonist, in healthy volunteers
26. Pharmacological profile of almotriptan, a novel antimigraine agent
27. The pharmacokinetics and tolerability of almotriptan in renal impairment
28. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug
29. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug
30. Absolute bioavailability of oral and subcutaneous almotriptan
31. Pharmacokinetics of oral almotriptan during and outside a migraine attack
32. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans
33. Almotriptan: Clinical profile
34. 1D/1B agonist
35. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans
36. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers
37. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers
38. Effect of ketoconazole on the clearance of the antimigraine compound, almotriptan, in humans
39. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers
40. Dose-finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine
41. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study
42. 1B/1D agonist, compared with sumatriptan 100 mg
43. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallel-group, optimum-dose comparison
44. A 6-month open-label study of orally administered almotriptan in migraine patients
45. Tolerability and efficacy of almotriptan in the long-term treatment of migraine
46. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan
47. Section Ib. Migraine and other headache syndromes: Description and diagnostic criteria
48. Guidelines for controlled trials of drugs in migraine
49. Guidelines for controlled trials of drugs in migraine
50. Efficacy and tolerability of oral almotriptan in the treatment of migraine
51. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan
52. Beneficial effects of early intervention with almotriptan during long-term treatment of migraine
53. Advantageous tolerability of almotriptan 12.5 mg compared with sumatriptan 100 mg
54. Is chest pain after sumatritpan oesophageal in origin?
55. Effect of the anti-migraine drug sumatriptan on muscle energy metabolism: Relationship to side-effects
56. Coronary side-effect potential of current and prospective antimigraine drugs
57. Cost savings in migraine associated with less chest pain on new triptan therapy
58. Guidelines for the management of headache
59. An economic decision model for chest symptom events associated with triptan use in migraine
60. Economic analysis of acute migraine: Results from a controlled comparison of almotriptan and sumatriptan
61. Treatment of migraine headaches
62. Diagnosis and management of migraine
63. 1B/1D agonist: Differential effects of propranolol, nadolol and metoprolol
64. Therapie der migräne-attacke und migräneprophylaxe: Empfehlungen der Deutschen Migräne- und Kopfschmerzgesellschaft (DMKG)
65. 1 receptor agonists for migraine: Comparative considerations
66. Side effects of ergotamine
67. The cost effectiveness of stratified care in the management of migraine
68. Acute migraine treatment outcome measures: A clinician's view
69. Present and future of 5-HT receptor agonists as antimigraine drugs
70. The scientific basis of medication choice in symptomatic migraine treatment
71. 1B/1D receptor agonists in migraine: Comparative pharmacology and its therapeutic implications
72. 1D) agonists and other agents in acute migraine
73. Zolmitriptan: A review of its use in migraine
74. Rizatriptan: A review of its efficacy in the management of migraine
75. Eletriptan
76. Sumatriptan in a clinical practice: A 2-year review of 453 migraine patients
77. Chest symptoms after sumatriptan: A two-year clinical practice review in 735 consecutive migraine patients
78. Naratriptan
79. Sumatriptan: An updated review of its use in migraine
80. 1B/1D agonist rizatritpan in healthy volunteers
81. Safety and rational use of the triptans
82. Methodologic issues in acute migraine clinical trials
83. Monitoring of acute migraine attacks: Placebo response and safety data
84. The pharmacology of headache
85. A triptan too far?
86. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: A randomized, double-blind, international study
87. Crossover comparison of rizatritptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
88. Comparison of the efficacy of oral eletritpan and oral sumatritpan for the acute treatment of migraine: Combined analysis across three clinical trials
89. A comparison of the efficacy, safety and tolerability of naratriptan and sumatriptan
90. 1B/1D agonists) in acute migraine treatment: A metaanalysis of 53 trials
91. 1B/1D agonists: Is there a cause for concern?
92. What matters is not the differences between triptans, but the differences between patients
93. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agent: A comparative review
94. Migraine treatment and mistreatment: Primum non nocere
95. Issues in the measurement of satisfaction with treatment
96. How to assess patient preference of migraine treatments
97. Optimum-dose determination of the triptans
98. Assessing patient preference in migraine treatment